Clinical Trial TitleA phase III randomized trial for patients with de novo AML using bortezomib and sorafenib (IND# I14480, NSC# 681239, NSC# 724772) for patients with high allelic ratio FLT3/ITD.
Clinical Trial Protocol Description:
To compare event free survival (EFS) and overall survival (OS) in patients with de nova acute myeloid leukemia (AML) without high allelic ratio FLT3/ITD+mutations who are randomized to standard therapy versus bortezomib/standard combination therapy.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are less that 30 years of age at the time of study enrollment.
- Have been newly diagnosed with de novo acute myelogenous leukemia.
This is a partial list of eligibility requirements.